Device Trial Radar · NCT07896902
Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in Emphysema
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Apr 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Apreo Health, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- University of Alabama at Birmingham; University of Kansas Medical Center
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 40 years, up to 84 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to provide a regional, mechanistic characterization of pulmonary ventilation changes following treatment with the Apreo BREATHE System, using hyperpolarized ¹²⁹Xe MRI, in BREATHE-3 participants. BREATHE-Xe is designed to generate mechanistic signals regarding whether airway scaffolds reduce ventilation defects, improve gas exchange, and correlate with CT and spirometric/plethysmographic changes observed in BREATHE-3. Findings support mechanistic interpretation and future hypothesis generation.
Conditions
- Air Trapping
- Emphysema
- Hyperinflation
Interventions
Hyperpolarized Xenon MRIDrug
Hyperpolarized Xenon MRI (HP ¹²#Xe) is a radiation-free imaging technique that boosts signal strength to create high-resolution images of how gas moves through the lungs. By tracking inhaled gas across separate breath-holds, it measures airflow blockage, tissue transfer efficiency, and gas uptake by red blood cells, while a washout test maps how well the lungs clear gas. It has been applied to characterize pulmonary impairment in COPD and emphysema and to detect regional ventilation changes following bronchoscopic interventions.
Apreo BREATHE Airway ScaffoldDevice
The experimental treatment involves placement of up to 6 Apreo BREATHE Airway Scaffolds (up to 3 per lung), in a single procedure using bronchoscopy and fluoroscopy. Treatment group subjects will also receive optimal medical management (OMM). The BREATHE Airway Scaffold implant procedure occurs under the BREATHE-3 main study. This procedure is not part of the BREATHE-Xe study, which focuses on changes in regional ventilation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary EndpointTime frame: 6 Months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of Kansas Medical Center (KUMC)
Kansas City, Kansas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.